Sanofi secures rights to Ascenta's experimental cancer drugs

06/6/2010 | Reuters

Biotech firm Ascenta Therapeutics agreed to license its cancer drug candidates, including MI-773 and MI-519-64, to Sanofi-Aventis. The deal entitles Ascenta to get as much as $398 million from Sanofi.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA